(Q43988921)

28 November 2017

title

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. (English)

1 reference

28 November 2017

main subject

liver transplantation

1 reference

1 reference

1 reference

6

Kris V Kowdley

1 reference

28 November 2017

Robert J Fontana

1

1 reference

28 November 2017

Emmet B Keeffe

2

1 reference

28 November 2017

William Carey

3

1 reference

28 November 2017

Michael Fried

4

1 reference

28 November 2017

Rajender Reddy

5

1 reference

28 November 2017

Consuelo Soldevila-Pico

7

1 reference

28 November 2017

Leslie A McClure

8

1 reference

28 November 2017

Anna S F Lok

9

1 reference

28 November 2017

National Institutes of Health Hepatitis B Virus Orthotopic Liver Transplantation Study Group

10

1 reference

28 November 2017

publication date

1 May 2002

1 reference

28 November 2017

published in

Liver Transplantation

1 reference

28 November 2017

volume

8

1 reference

28 November 2017

issue

5

1 reference

28 November 2017

page(s)

433-439

1 reference

Hepatitis B: Evolving Epidemiology and Implications for Control

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

A model to predict survival in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Selective loss of nucleoside carrier expression in rat hepatocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2002.32983

21 January 2018

Identifiers

DOI

10.1053/JLTS.2002.32983

1 reference

28 November 2017

1 reference